Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sweta T. Kothari"'
Publikováno v:
Medicinal Chemistry Research. 27:1013-1025
A series of chalcone derivatives (1a–2i) were designed based on isoliquiritigenin (the most active natural chalcone non-competitive neuraminidase (NA) inhibitor). Molecular modeling studies revealed that isoliquiritigenin and its designed analogs o
Autor:
Devanshi J. Gohil, Abhay Chowdhary, Sudha Srivastava, Sweta T. Kothari, Anand S. Chintakrindi, Mamata Joshi, H. Gonsalves, Khushboo D Malbari, Meena Kanyalkar
Publikováno v:
Acta virologica. 62:179-190
Considering the need for discovery of new antiviral drugs, in view to combat the issue of resistance particularly to anti-influenza drugs, a series of 2'-amino, 3'-amino and 2', 4'-dihydroxy chalcone derivatives were designed. Structure-based drug de
Autor:
Abhay Chowdhary, Rhuta Meharunkar, Devanshi J. Gohil, Rajas Warke, Sweta T. Kothari, Pramod Shinde, Ranjana A Deshmukh
Publikováno v:
Current Microbiology. 74:899-907
Pandemic influenza A (H1N1) 2009 virus was first detected in India in May 2009 which subsequently became endemic in many parts of the country. Influenza A viruses have the ability to evade the immune response through its ability of antigenic variatio
Autor:
Abhay Chowdhary, Anand S. Chintakrindi, Devanshi J. Gohil, Elvis A. F. Martis, Evans C. Coutinho, Meena Kanyalkar, Sweta T. Kothari
Publikováno v:
Current Computer Aided-Drug Design. 12:272-281
Background: With cases of emergence of drug resistance to the current competitive inhibitors of neuraminidase (NA) such as oseltamivir and zanamavir, there is a present need for an alternative approach in the treatment of avian influenza. With this i
Autor:
Khushboo D Malbari, Sweta T. Kothari, Anand S. Chintakrindi, Meena Kanyalkar, Devanshi J. Gohil, Lata R. Ganji, Mamata Joshi
Publikováno v:
Molecular diversity. 23(4)
The rate of mutability of pathogenic H1N1 influenza virus is a threat. The emergence of drug resistance to the current competitive inhibitors of neuraminidase, such as oseltamivir and zanamivir, attributes to a need for an alternative approach. The d
Autor:
Sweta T. Kothari, Devanshi J. Gohil, Amol Chaudhari, Prasad S. Kulkarni, Bhagwat Gunale, Abhay Chowdhary, Ranjana A Deshmukh
Publikováno v:
Viral Immunology. 29:159-163
Measles, Mumps, and Rubella (MMR) are vaccine preventable viral infections, which cause significant mortality and morbidity globally. Increased incidence rates of these infectious diseases are observed in young adults. Information on seroprevalence d
Publikováno v:
Immunobiology. 220:1170-1176
Dengue, the most rampant zoonotic viral disease in tropics, contributes to 14% of acute febrile illness cases globally. Encephalitis in primary Dengue fever, with/without haemorrhage has been reported occasionally. Our study presents novel evidence f
Autor:
Vainav Patel, Sukeshani Salwe, Rahul Ashok Gosavi, Abhay Chowdhary, Ritwik Dahake, Sweta T. Kothari, Ranjana A Deshmukh, Sandeepan Mukherjee
Publikováno v:
Bone Marrow Research, Vol 2018 (2018)
Bone Marrow Research
Bone Marrow Research
12–14 days of culturing of bone marrow (BM) cells containing various growth factors is widely used method for generating dendritic cells (DCs) from suspended cell population. Here we compared flask culture method and commercially available CD11c Po
Autor:
Anand S. Chintakrindi, Sweta T. Kothari, Pramod Shinde, Abhay Chowdhary, Meena Kanyalkar, Devanshi J. Gohil, Rhuta Meharunkar, Ranjana A Deshmukh, Rajas Warke
Publikováno v:
Infection, Genetics and Evolution. 29:75-81
Objective From its first instance in 1977, resistance to amantadine, a matrix (M2) inhibitor has been increasing among influenza A/H3N2, thus propelling the use of oseltamivir, a neuraminidase (NA) inhibitor as a next line drug. Information on drug s
Autor:
Abhay Chowdhary, Shreewardhan Rajopadhye, Soumen Roy, Deepak Patil, Ritwik Dahake, Sweta T. Kothari, Ranjana A Deshmukh
Publikováno v:
Indian Journal of Virology. 24:220-226
Influenza is a serious respiratory illness which can be debilitating and cause complications that lead to hospitalization and death. Although influenza vaccine can prevent influenza virus infection, the only therapeutic options to treat influenza vir